Literature DB >> 22988862

Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2.

Youren Tong1, Jie Shen.   

Abstract

Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic cause of PD (Parkinson's disease). To investigate how mutations in LRRK2 cause PD, we generated LRRK2 mutant mice either lacking its expression or expressing the R1441C mutant form. Homozygous R1441C knockin mice exhibit no dopaminergic neurodegeneration or alterations in steady-state levels of striatal dopamine, but they show impaired dopamine neurotransmission, as was evident from reductions in amphetamine-induced locomotor activity and stimulated catecholamine release in cultured chromaffin cells as well as impaired dopamine D2 receptor-mediated functions. Whereas LRRK2-/- brains are normal, LRRK2-/- kidneys at 20 months of age develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins, impairment of the autophagy-lysosomal pathway, and increases in apoptotic cell death, inflammatory responses and oxidative damage. Our further analysis of LRRK2-/- kidneys at multiple ages revealed unique age-dependent biphasic alterations of the autophagic activity, which is unchanged at 1 month of age, enhanced at 7 months, but reduced at 20 months. Levels of α-synuclein and protein carbonyls, a general oxidative damage marker, are also decreased in LRRK2-/- kidneys at 7 months of age. Interestingly, this biphasic alteration is associated with increased levels of lysosomal proteins and proteases as well as progressive accumulation of autolysosomes and lipofuscin granules. We conclude that pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988862      PMCID: PMC9112632          DOI: 10.1042/BST20120112

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   4.919


  50 in total

Review 1.  The DRD2 gene in psychiatric and neurological disorders and its phenotypes.

Authors:  E P Noble
Journal:  Pharmacogenomics       Date:  2000-08       Impact factor: 2.533

2.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.

Authors:  Manabu Funayama; Kazuko Hasegawa; Etsuro Ohta; Noriko Kawashima; Masaru Komiyama; Hisayuki Kowa; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

3.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

4.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

Authors:  Sreeganga Chandra; Gilbert Gallardo; Rafael Fernández-Chacón; Oliver M Schlüter; Thomas C Südhof
Journal:  Cell       Date:  2005-11-04       Impact factor: 41.582

5.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

6.  Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.

Authors:  Tohru Kitada; Antonio Pisani; Douglas R Porter; Hiroo Yamaguchi; Anne Tscherter; Giuseppina Martella; Paola Bonsi; Chen Zhang; Emmanuel N Pothos; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

Review 7.  Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

Review 8.  A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

Authors:  S D Robertson; H J G Matthies; A Galli
Journal:  Mol Neurobiol       Date:  2009-02-06       Impact factor: 5.590

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

View more
  6 in total

1.  Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.

Authors:  Guodong Huang; Daniel W Bloodgood; Jongkyun Kang; Anu Shahapal; Phoenix Chen; Konstantin Kaganovsky; Jae-Ick Kim; Jun B Ding; Jie Shen
Journal:  J Neurosci       Date:  2022-05-09       Impact factor: 6.709

2.  ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.

Authors:  Yuangang Zhu; Chunyan Wang; Mei Yu; Jie Cui; Liang Liu; Zhiheng Xu
Journal:  Protein Cell       Date:  2013-09-10       Impact factor: 14.870

Review 3.  The role of the LRRK2 gene in Parkinsonism.

Authors:  Jie-Qiong Li; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2014-11-12       Impact factor: 14.195

Review 4.  Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.

Authors:  Johanna Duda; Christina Pötschke; Birgit Liss
Journal:  J Neurochem       Date:  2016-03-23       Impact factor: 5.372

Review 5.  What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?

Authors:  David A Loeffler; Jan O Aasly; Peter A LeWitt; Mary P Coffey
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

6.  Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.

Authors:  Qi Qin; Lian-Teng Zhi; Xian-Ting Li; Zhen-Yu Yue; Guo-Zhong Li; Hui Zhang
Journal:  CNS Neurosci Ther       Date:  2016-12-09       Impact factor: 5.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.